Galectin Therapeutics stockholders approve all proposals at 2022 annual meeting

Election of Directors Name Votes For Votes Withheld Broker Non-Votes Gilbert F. Amelio, Ph.D. 16,657,514 1,492,785 18,758,920 James C. Czirr 17,108,078 1,042,221 18,758,920 Kary Eldred 17,277,004 873,295 18,758,920 Kevin D. Freeman 16,987,116 1,163,183 18,758,920 Joel Lewis 17,492,649 657,650 18,758,920 Gilbert S. Omenn, M.D., Ph.D. 17,274,427 875,872 18,758,920 Marc Rubin, M.D. 16,865,340 1,284,959 18,758,920 Elissa J. Schwartz, Ph.D. 17,541,115 609,184 18,758,920 Harold H. Shlevin, Ph.D. 17,361,708 788,591 18,758,920 Richard E. Uihlein, Chairman 17,611,340 538,959 18,758,920 Richard A. Zordani 17,396,959 753,340 18,758,920

Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2022 Votes For Votes Against Votes Abstain 36,267,085 370,624 271,510

Authorize and approve for purposes of complying with Nasdaq Listing Rule 5635, the issuance of more than 20% of our issued and outstanding shares of common stock in connection with our line of credit provided by Richard E. Uihlein, our Chairman of the Board of Directors. The number of shares to be issued includes a maximum of 20,000,000 common shares in exchange for $60,000,000 for the principal of the line of credit, 1,700,000 of common shares for stock purchase warrants issued in connection with the line of credit, and common shares issuable in exchange for accrued interest on the line of credit. Votes For Votes Against Votes Abstain Broker Non-Votes 16,845,581 1,146,064 158,654 18,758,920

To vote on a non-binding advisory resolution to approve executive compensation . Votes For Votes Against Votes Abstain Broker Non-Votes 16,271,959 1,450,200 428,140 18,758,920